S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:OBSV

ObsEva (OBSV) Stock Forecast, Price & News

$0.06
-0.01 (-14.29%)
(As of 09/22/2023 ET)
Compare
Today's Range
$0.06
▼
$0.08
50-Day Range
$0.04
▼
$0.10
52-Week Range
$0.08
▼
$2.14
Volume
6,980 shs
Average Volume
8.94 million shs
Market Capitalization
$4.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

OBSV stock logo

About ObsEva (NASDAQ:OBSV) Stock

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

OBSV Price History

OBSV Stock News Headlines

September 17, 2023 | americanbankingnews.com
ObsEva (NASDAQ:OBSV) Coverage Initiated by Analysts at StockNews.com
June 18, 2023 | fool.com
ObsEva (NASDAQ: OBSV)
September 24, 2023 | Legacy Research (Ad)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
March 31, 2023 | finance.yahoo.com
ObsEva Files Year End 2022 Financial Statements
March 15, 2023 | finance.yahoo.com
ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023
March 13, 2023 | markets.businessinsider.com
ObsEva Names Fabien De Ladonchamps CEO, Ernest Loumaye Interim Chairman
March 13, 2023 | finance.yahoo.com
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
March 3, 2023 | benzinga.com
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 24, 2023 | Legacy Research (Ad)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
March 3, 2023 | investorplace.com
Why Is ObsEva (OBSV) Stock Up 93% Today?
February 24, 2023 | investorplace.com
Why ObsEva (OBSV) Stock Is Down 36% Today
February 24, 2023 | finance.yahoo.com
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
January 12, 2023 | uk.finance.yahoo.com
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
December 19, 2022 | finance.yahoo.com
ObsEva Announces Dismissal of Moratorium Proceedings
December 14, 2022 | finance.yahoo.com
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
December 1, 2022 | finance.yahoo.com
ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates
December 1, 2022 | finance.yahoo.com
ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update
October 27, 2022 | finance.yahoo.com
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings
October 16, 2022 | finance.yahoo.com
ObsEva SA (OBSV)
October 14, 2022 | markets.businessinsider.com
ObsEva : China Approves Yuyuan Bioscience's IND Application For Phase 1 Trial Of Nolasiban
October 13, 2022 | finance.yahoo.com
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China - Yahoo Finance
October 13, 2022 | marketscreener.com
ObsEva Says Partner Yuyuan Bioscience Obtained Regulatory Nod for Nolasiban Drug Trial in China - Marketscreener.com
October 13, 2022 | benzinga.com
ObsEva Announces IND Approval for Yuyuan Bioscience's Phase 1 Clinical Trial of Nolasiban in China - ObsE - Benzinga
October 13, 2022 | marketscreener.com
ObsEva's Chinese Partner Wins Regulatory Nod To Launch Early-stage Trial Of Clinical Pregnancy Drug - Marketscreener.com
October 13, 2022 | globenewswire.com
ObsEva Announces IND Approval for Yuyuan Bioscience's Phase - GlobeNewswire
October 13, 2022 | finance.yahoo.com
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
October 6, 2022 | reuters.com
OBSV.PH - Obseva SA | Stock Price & Latest News | Reuters
See More Headlines
Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

OBSV Company Calendar

Last Earnings
11/04/2021
Today
9/24/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OBSV
CUSIP
N/A
CIK
1685316
Web
www.obseva.com
Phone
(122) 552-3840
Fax
N/A
Employees
48
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-58,380,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-416.36%
Return on Assets
-92.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.61
Quick Ratio
0.61

Sales & Book Value

Annual Sales
$20.11 million
Price / Sales
0.23
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.41 per share
Price / Book
0.15

Miscellaneous

Outstanding Shares
77,971,000
Free Float
66,743,000
Market Cap
$4.68 million
Optionable
Not Optionable
Beta
0.68
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • William M. Brown
    Chief Executive & Financial Officer
  • Elke Bestel
    VP, Head-Drug Safety & Pharmacovigilance
  • Katja Buhrer
    Chief Strategy Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













OBSV Stock - Frequently Asked Questions

How have OBSV shares performed in 2023?

ObsEva's stock was trading at $0.1450 at the beginning of 2023. Since then, OBSV shares have decreased by 58.6% and is now trading at $0.06.
View the best growth stocks for 2023 here.

How were ObsEva's earnings last quarter?

ObsEva SA (NASDAQ:OBSV) posted its earnings results on Thursday, November, 4th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.23.

What other stocks do shareholders of ObsEva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).

When did ObsEva IPO?

(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is ObsEva's stock symbol?

ObsEva trades on the NASDAQ under the ticker symbol "OBSV."

Who are ObsEva's major shareholders?

ObsEva's stock is owned by many different institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%).

How do I buy shares of ObsEva?

Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ObsEva's stock price today?

One share of OBSV stock can currently be purchased for approximately $0.06.

How much money does ObsEva make?

ObsEva (NASDAQ:OBSV) has a market capitalization of $4.68 million and generates $20.11 million in revenue each year. The company earns $-58,380,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

How can I contact ObsEva?

ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The official website for the company is www.obseva.com. The company can be reached via phone at (122) 552-3840 or via email at ir@obseva.ch.

This page (NASDAQ:OBSV) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -